Harbinger Health announced a $100 million funding round led by Flagship Pioneering to advance its cancer detection technology 1 3 The company introduced Resolve, a new category of blood-based multi-cancer detection tests designed to reduce diagnostic uncertainty between cancer suspicion and diagnosis 1 3 Resolve is expected to be commercially available in the second half of 2026 3 The platform aims to minimize false negatives and false positives while enabling faster clinical decision-making 1 The funding also supports further development of Harbinger's HarbingerHx software platform and the ongoing PROCARES prospective validation study, which is 88% enrolled 1 3 Harbinger emerged from stealth in 2021 with $50 million from Flagship Pioneering and raised $140 million in Series B in 2023 1 The company's technology combines artificial intelligence with cancer biology insights to detect early-stage cancers through low-cost blood tests targeting multiple cancer types 3 ...
- Get link
- X
- Other Apps